Background The Pediatric AIDS Clinical Trials Group Protocol 076 reported a reduction in the rate of perinatal transmission of the human immunodeficiency virus (HIV) from 25.5 percent to 8.3 percent with a three-part regimen of zidovudine given ante partum, intra partum, and to the newborn.
We examined the effects of abbreviated zidovudine regimens on perinatal HIV transmission using data from the HIV polymerase-chain-reaction (PCR) testing service of the New York State Department of Health.
Pregnant women who received abbreviated regimens rather than the recommended regimens did so because of limited prenatal care or by choice.
Methods The requisition form used by the PCR testing service included information on the demographic characteristics of the infants and the timing of any perinatal treatment with zidovudine.
We also analyzed data on the timing of zidovudine prophylaxis collected by chart review in a subgroup of 454 infants as a means of validating the results in the entire cohort.
Results From August 1,1995, through January 31,1997, specimens from 939 HIV-exposed infants who were 180 days of age or younger were submitted for PCR testing.
The rates of perinatal HIV transmission varied depending on when zidovudine prophylaxis was begun.
When treatment was begun in the prenatal period, the rate of HIV transmission was 6.1 percent (95 percent confidence interval, 4.1 to 8.9 percent) ; when begun intra partum, the rate was 10.0 percent. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Virus immunodéficience humaine, Lentivirus, Retroviridae, Virus, Protocole thérapeutique, Zidovudine, Prévention, Périnatal, Transmission verticale, Forme abrégée, Efficacité traitement, Femelle, Homme, Pyrimidine nucléoside, Didésoxynucléoside, Immunopathologie, Immunodéficit, Antiviral
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Human immunodeficiency virus, Lentivirus, Retroviridae, Virus, Therapeutic protocol, Zidovudine, Prevention, Perinatal, Vertical transmission, Abbreviated form, Treatment efficiency, Female, Human, Pyrimidine nucleoside, Dideoxynucleoside, Immunopathology, Immune deficiency, Antiviral
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0006968
Code Inist : 002B05C02D. Création : 31/05/1999.